US Patent

US9107921 — Oral dosage forms for oxygen containing active agents and oxyl-containing polymers

Formulation · Assigned to Spriaso LLC · Expires 2032-01-03 · 6y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a pharmaceutical tablet for oral administration that includes a tri-oxy active agent and a release rate controlling non-ionic oxyl-containing hydrophilic polymer.

USPTO Abstract

A pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The tablet is a matrix tablet and a single-dose administration of one or more tablets to a subject under fasted conditions provides a mean Cm˜ for each of the first active agent and the second active agent that is 70% to 135% of a respective mean Cm˜ provided by administering an immediate release oral dosage form to a subject under fasted conditions every 4 to 6 hours over a 12 hour time period, wherein cumulative dosage amounts administered over the 12 hour time period of each active agent is equivalent to the respective amount of each active agent in the pharmaceutical tablet.

Drugs covered by this patent

Patent Metadata

Patent number
US9107921
Jurisdiction
US
Classification
Formulation
Expires
2032-01-03
Drug substance claim
No
Drug product claim
Yes
Assignee
Spriaso LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.